LONG MINI-FUTURE - GENMAB | Market Closed - Deutsche Boerse AG 02:05:03 2024-07-12 pm EDT | ||
| 4.1 EUR | +19.88% |
|
| Current month | +48.01% | ||
| 1 month | +1.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 4.1 | +19.88% |
| 24-07-11 | 3.42 | +17.12% |
| 24-07-10 | 2.92 | -3.95% |
| 24-07-09 | 3.04 | +7.42% |
| 24-07-08 | 2.83 | -1.74% |
Delayed Quote Deutsche Boerse AG
Last update July 12, 2024 at 02:05 pm EDT
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VP12FX |
| ISIN | DE000VP12FX5 |
| Date issued | 2020-03-30 |
| Strike | 1,536 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.88 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 26.13 € |
|---|---|
| Lowest since issue | 0.83 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,846
DKK
Average target price
2,446
DKK
Spread / Average Target
+32.56%
- Stock Market
- Certificates
- Certificat
